CPT code 82610 denotes a quantitative laboratory assay for cystatin C, a blood protein used as a marker of kidney function. This test is clinically important for estimating glomerular filtration and for assessing renal status when creatinine-based estimates may be limited. Nationally, cystatin C testing supports diagnostic evaluation, medication dosing considerations, and monitoring of chronic kidney disease progression.

Key payers included in the analysis are Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of what the code represents, typical sites of service, and which major payers are relevant to coverage discussions. The publication summarizes clinical context for when cystatin C is used and outlines the types of benchmarks and policy topics that typically accompany laboratory code reviews, including utilization patterns, reimbursement considerations, and coding guidance.

The report provides practical reference information for billing and revenue cycle teams, laboratory directors, and policy analysts seeking a national perspective on CPT code 82610. Data not available in the input are identified explicitly where applicable.